180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.8 ^USD	+1.76%		-1.10%	-55.63%

Mar. 25	180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 11	180 Life Sciences Corp. Announces Board Changes	CI

180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023

March 25, 2024 at 06:15 am EDT

180 Life Sciences Corp. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 19.94 million compared to USD 38.73 million a year ago.

Basic loss per share from continuing operations was USD 52.59 compared to USD 387.18 a year ago.

Latest news about 180 Life Sciences Corp.

180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
180 Life Sciences Corp. Announces Board Changes	Mar. 11	CI
180 Life Sciences Corp. Appoints Blair Jordan as A Member of the Board of Directors	Feb. 29	CI
180 Life Sciences to Conduct 1-For-19 Reverse Stock Split	Feb. 26	MT
180 Life Sciences Corp. announced a financing transaction	Feb. 20	CI
180 Life Sciences Corp. Announces Board Resignations	Dec. 21	CI
180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors	Dec. 20	CI
180 Life Sciences Hires Financial Adviser to Help Explore Strategic Alternatives	Dec. 04	CI
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives	Dec. 03	CI
180 Life Sciences Announces Review of Strategic Alternatives	Nov. 28	CI
Certain Warrants of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	Nov. 12	CI
Certain Stock Options of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	Nov. 12	CI
Certain Common Stock of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	Nov. 12	CI
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency	23-10-18	CI
180 Life Sciences Corp. and Oxford University Innovation Limited Enter into a Termination Letter, Formally Terminate the License	23-09-28	CI
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Top Premarket Gainers	23-08-09	MT
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake	23-08-07	CI
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment	23-08-03	CI
180 Life Sciences Corp. Announces the Filing of A Provisional Patent Describing the Combination of CBD with GLP-1 Agonists to Suppress Appetite	23-07-31	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Growth Index	23-06-23	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Value Index	23-06-23	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Index	23-06-23	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell Microcap Index	23-06-23	CI

Chart 180 Life Sciences Corp.

Duration

Period

More charts

Company Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
180 LIFE SCIENCES CORP.	-55.63%	1.53M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs